A Moving Target—Vancomycin Therapeutic Monitoring

Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines published in March 2020 recommend area under...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Pediatric Infectious Diseases Society 2020-09, Vol.9 (4), p.474-478
Hauptverfasser: Burns, Alaina N, Goldman, Jennifer L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 478
container_issue 4
container_start_page 474
container_title Journal of the Pediatric Infectious Diseases Society
container_volume 9
creator Burns, Alaina N
Goldman, Jennifer L
description Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines published in March 2020 recommend area under the curve (AUC) based TDM for vancomycin instead of trough-only TDM. In this review, we discuss the rationale behind the change in TDM recommendations, describe two approaches for calculating vancomycin AUC in clinical practice, and address considerations for integrating vancomycin AUC TDM into pediatric clinical practice. Our primary goal is to provide pediatric clinicians with a resource for implementing vancomycin AUC monitoring into clinical care.
doi_str_mv 10.1093/jpids/piaa078
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2427523225</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2427523225</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-7cc330b0e2cd843f1ea8c4e469576b4cec4f6d56177987df36a56ee11c3bee753</originalsourceid><addsrcrecordid>eNpNkLtOwzAYhS0EElXpyN6RJdR3J2NVcZOKWAKr5fz5U1y1cbBTpG48BE_Ik5DSDpzlnOHTGT5Crhm9ZbQQs3Xn6zTrvHPU5GdkxKnMM8OpOf-3L8kkpTUdohVTuRwRMZ8-h0_frqaliyvsf76-31wLYbsH307Ld4yuw13vYcBa34c4oFfkonGbhJNTj8nr_V25eMyWLw9Pi_kyA0GLPjMAQtCKIoc6l6Jh6HKQKHWhjK4kIMhG10ozY4rc1I3QTmlExkBUiEaJMbk5_nYxfOww9XbrE-Bm41oMu2S55EZxwfkBzY4oxJBSxMZ20W9d3FtG7cGP_fNjT37ELyKAW1o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2427523225</pqid></control><display><type>article</type><title>A Moving Target—Vancomycin Therapeutic Monitoring</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Burns, Alaina N ; Goldman, Jennifer L</creator><creatorcontrib>Burns, Alaina N ; Goldman, Jennifer L</creatorcontrib><description>Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines published in March 2020 recommend area under the curve (AUC) based TDM for vancomycin instead of trough-only TDM. In this review, we discuss the rationale behind the change in TDM recommendations, describe two approaches for calculating vancomycin AUC in clinical practice, and address considerations for integrating vancomycin AUC TDM into pediatric clinical practice. Our primary goal is to provide pediatric clinicians with a resource for implementing vancomycin AUC monitoring into clinical care.</description><identifier>ISSN: 2048-7207</identifier><identifier>EISSN: 2048-7207</identifier><identifier>DOI: 10.1093/jpids/piaa078</identifier><language>eng</language><ispartof>Journal of the Pediatric Infectious Diseases Society, 2020-09, Vol.9 (4), p.474-478</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-7cc330b0e2cd843f1ea8c4e469576b4cec4f6d56177987df36a56ee11c3bee753</citedby><cites>FETCH-LOGICAL-c309t-7cc330b0e2cd843f1ea8c4e469576b4cec4f6d56177987df36a56ee11c3bee753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Burns, Alaina N</creatorcontrib><creatorcontrib>Goldman, Jennifer L</creatorcontrib><title>A Moving Target—Vancomycin Therapeutic Monitoring</title><title>Journal of the Pediatric Infectious Diseases Society</title><description>Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines published in March 2020 recommend area under the curve (AUC) based TDM for vancomycin instead of trough-only TDM. In this review, we discuss the rationale behind the change in TDM recommendations, describe two approaches for calculating vancomycin AUC in clinical practice, and address considerations for integrating vancomycin AUC TDM into pediatric clinical practice. Our primary goal is to provide pediatric clinicians with a resource for implementing vancomycin AUC monitoring into clinical care.</description><issn>2048-7207</issn><issn>2048-7207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpNkLtOwzAYhS0EElXpyN6RJdR3J2NVcZOKWAKr5fz5U1y1cbBTpG48BE_Ik5DSDpzlnOHTGT5Crhm9ZbQQs3Xn6zTrvHPU5GdkxKnMM8OpOf-3L8kkpTUdohVTuRwRMZ8-h0_frqaliyvsf76-31wLYbsH307Ld4yuw13vYcBa34c4oFfkonGbhJNTj8nr_V25eMyWLw9Pi_kyA0GLPjMAQtCKIoc6l6Jh6HKQKHWhjK4kIMhG10ozY4rc1I3QTmlExkBUiEaJMbk5_nYxfOww9XbrE-Bm41oMu2S55EZxwfkBzY4oxJBSxMZ20W9d3FtG7cGP_fNjT37ELyKAW1o</recordid><startdate>20200917</startdate><enddate>20200917</enddate><creator>Burns, Alaina N</creator><creator>Goldman, Jennifer L</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200917</creationdate><title>A Moving Target—Vancomycin Therapeutic Monitoring</title><author>Burns, Alaina N ; Goldman, Jennifer L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-7cc330b0e2cd843f1ea8c4e469576b4cec4f6d56177987df36a56ee11c3bee753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Burns, Alaina N</creatorcontrib><creatorcontrib>Goldman, Jennifer L</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the Pediatric Infectious Diseases Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burns, Alaina N</au><au>Goldman, Jennifer L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Moving Target—Vancomycin Therapeutic Monitoring</atitle><jtitle>Journal of the Pediatric Infectious Diseases Society</jtitle><date>2020-09-17</date><risdate>2020</risdate><volume>9</volume><issue>4</issue><spage>474</spage><epage>478</epage><pages>474-478</pages><issn>2048-7207</issn><eissn>2048-7207</eissn><abstract>Therapeutic drug monitoring (TDM) has been a common practice to optimize efficacy and safety of vancomycin. While vancomycin trough-only TDM has widely been integrated into pediatric clinical practice since 2009, recently updated vancomycin TDM guidelines published in March 2020 recommend area under the curve (AUC) based TDM for vancomycin instead of trough-only TDM. In this review, we discuss the rationale behind the change in TDM recommendations, describe two approaches for calculating vancomycin AUC in clinical practice, and address considerations for integrating vancomycin AUC TDM into pediatric clinical practice. Our primary goal is to provide pediatric clinicians with a resource for implementing vancomycin AUC monitoring into clinical care.</abstract><doi>10.1093/jpids/piaa078</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2048-7207
ispartof Journal of the Pediatric Infectious Diseases Society, 2020-09, Vol.9 (4), p.474-478
issn 2048-7207
2048-7207
language eng
recordid cdi_proquest_miscellaneous_2427523225
source Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
title A Moving Target—Vancomycin Therapeutic Monitoring
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A07%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Moving%20Target%E2%80%94Vancomycin%20Therapeutic%20Monitoring&rft.jtitle=Journal%20of%20the%20Pediatric%20Infectious%20Diseases%20Society&rft.au=Burns,%20Alaina%20N&rft.date=2020-09-17&rft.volume=9&rft.issue=4&rft.spage=474&rft.epage=478&rft.pages=474-478&rft.issn=2048-7207&rft.eissn=2048-7207&rft_id=info:doi/10.1093/jpids/piaa078&rft_dat=%3Cproquest_cross%3E2427523225%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2427523225&rft_id=info:pmid/&rfr_iscdi=true